| 1 |
Flora K, Hahn M, Rosen H, et al. Milk thistle (Silybum marianum) for the therapy of liver disease[J]. Am J Gastroenterol,1998,93(2):139-143.
|
| 2 |
Saller R, Meier R, Brignoli R. The use of silymarin in the treatment of liver diseases[J]. Drugs,2001,61(14):2035-2063.
|
| 3 |
Pradhan SC, Girish C. Hepatoprotective herbal drug, silymarin from experimental pharmacology to clinical medicine[J]. Indian J Med Res,2006,124(5):491-504.
|
| 4 |
Janiak B, Hansel R. Phytochemisch-pharmakognostische untersuchungen uber fructus cardui mariae[J]. Planta Med (Stuttg.),1960,8:71-84.
|
| 5 |
Tittel G, Wagner H. High-performance liquid chromatographic separation of silymarins and their determination in a raw extract of Silybum marianum Gaertn[J]. J Chromatogr,1977,135(2):499-501.
|
| 6 |
Katiyar SK. Silymarin and skin cancer prevention: anti-inflammatory, antioxidant and immunomodulatory effects (Review)[J]. Int J Oncol,2005,26(1):169-176.
|
| 7 |
Lee JS, Kim SG, Kim HK, et al. Silibinin polarizes Th1/Th2 immune responses through the inhibition of immunostimulatory function of dendritic cells[J]. J Cell Physiol,2007,210(2):385-397.
|
| 8 |
Krecman V, Skottová N, Walterová D, et al. Silymarin inhibits the development of diet-induced hypercholesterolemia in rats[J]. Planta Med,1998,64(2):138-142.
|
| 9 |
Skottová N, Krecman V. Silymarin as a potential hypocholesterolaemic drug[J]. Physiol Res,1998,47(1):1-7.
|
| 10 |
中华医学会肝病学分会脂肪肝和酒精性肝病学组[J]. 非酒精性脂肪性肝病诊疗指南(2010). 中华肝脏病杂志, 2010, 18(3):163-166.
|
| 11 |
中华医学会肝病学分会脂肪肝和酒精性肝病学组. 酒精性肝病诊疗指南(2010)[J]. 中华内科杂志,2010,49(4):3357-3360.
|
| 12 |
中华医学会肝病学分会药物性肝病学组. 药物性肝损伤诊治指南(2015年版)[J]. 临床肝胆病杂志,2015,31(11):1752-1768.
|
| 13 |
中华医学会感染病学分会，肝脏炎症及其防治专家共识专家委员会. 肝脏炎症及其防治专家共识[J]. 中华肝脏病杂志,2014,34(2):152-163.
|
| 14 |
Polachi N, Bai G, Li T, et al. Modulatory effects of silibinin in various cell signaling pathways against liver disorders and cancer--A comprehensive review[J]. Eur J Med Chem,2016,123:577-595.
|
| 15 |
Hackett ES, Twedt DC, Gustafson DL. Milk thistle and its derivative compounds: a review of opportunities for treatment of liver disease[J]. J Vet Intern Med,2013,27(1):10-16.
|
| 16 |
Fehér J, Láng I, Nékám K, et al. Effect of silibinin on the activity and expression of superoxide dismutase in lymphocytes from patients with chronic alcoholic liver disease[J]. Free Radic Res Commun,1987,3(6):373-377.
|
| 17 |
Zhang W, Hong R, Tian T. Silymarin’s protective effects and possible mechanisms on alcoholic fatty liver for rats[J]. Biomol Ther (Seoul),2013,21(4):264-269.
|
| 18 |
Salamone F, Galvano F, Cappello F, et al. Silibinin modulates lipid homeostasis and inhibits nuclear factor kappa B activation in experimental nonalcoholic steatohepatitis[J]. Transl Res,2012,159(6):477-486.
|
| 19 |
Nakamura A, Tajima K, Zolzaya K, et al. Protection from non-alcoholic steatohepatitis and liver tumourigenesis in high fat-fed insulin receptor substrate-1-knockout mice despite insulin resistance[J]. Diabetologia,2012,55(12):3382-3391.
|
| 20 |
Cacciapuoti F, Scognamiglio A, Palumbo R, et al. Silymarin in non alcoholic fatty liver disease[J]. World J Hepatol,2013,5(3):109-113.
|
| 21 |
Müzes G, Deák G, Láng I, et al. Effect of the bioflavonoid silymarin on the in vitro activity and expression of superoxide dismutase (SOD) enzyme[J]. Acta Physiol Hung,1991,78(1):3-9.
|
| 22 |
Kim M, Yang SG, Kim JM, et al. Silymarin suppresses hepatic stellate cell activation in a dietary rat model of non-alcoholic steatohepatitis: analysis of isolated hepatic stellate cells[J]. Int J Mol Med,2012,30(3):473-479.
|
| 23 |
Aghazadeh S, Amini R, Yazdanparast R, et al. Anti-apoptotic and anti-inflammatory effects of Silybum marianum in treatment of experimental steatohepatitis[J]. Exp Toxicol Pathol,2011,63(6):569-574.
|
| 24 |
McCarty MF. Potential utility of natural polyphenols for reversing fat-induced insulin resistance[J]. Med Hypotheses,2005,64(3):628-635.
|
| 25 |
Prakash P, Singh V, Jain M, et al. Silymarin ameliorates fructose induced insulin resistance syndrome by reducing de novo hepatic lipogenesis in the rat[J]. Eur J Pharmacol,2014,727:15-28.
|
| 26 |
Feldstein AE, Canbay A, Angulo P, et al. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis[J]. Gastroenterology,2003,125(2):437-443.
|
| 27 |
Kim S, Choi JH, Lim HI, et al. Silibinin prevents TPA-induced MMP-9 expression and VEGF secretion by inactivation of the Raf/MEK/ERK pathway in MCF-7 human breast cancer cells[J]. Phytomedicine,2009,16(6-7):573-580.
|
| 28 |
Zhang Y, Hai J, Cao M, et al. Silibinin ameliorates steatosis and insulin resistance during non-alcoholic fatty liver disease development partly through targeting IRS-1/PI3K/Akt pathway[J]. Int Immunopharmacol,2013,17(3):714-720.
|
| 29 |
Rosso N, Marin V, Giordani A, et al. The pros and the cons for the use of silybin-rich oral formulations in treatment of liver damage (NAFLD in particular)[J]. Curr Med Chem,2015,22(25):2954-2971.
|
| 30 |
Bouderba S, Sanchez-Martin C, Villanueva GR, et al. Beneficial effects of silibinin against the progression of metabolic syndrome, increased oxidative stress, and liver steatosis in Psammomys obesus, a relevant animal model of human obesity and diabetes[J]. J Diabetes,2014,6(2):184-192.
|
| 31 |
褚扬，李伟，韩建平, 等. 水飞蓟宾胶囊在中国健康志愿者体内的药代动力学研究[J]. 中国药理学通报2009,25(12):1669-1672.
|
| 32 |
赵暖，栾立标. 水飞蓟宾-磷脂复合物的药代动力学和药效学研究进展[J]. 药学进展,2006,30(7):295-299.
|
| 33 |
李伟，高钧，丁宁, 等. 水飞蓟宾-卵磷脂复合物对水飞蓟素胶囊的相对生物利用度研究[J]. 中国新药杂志,2006,15(10):817-819.
|
| 34 |
Solhi H, Ghahremani R, Kazemifar AM, et al. Silymarin in treatment of non-alcoholic steatohepatitis: a randomized clinical trial[J]. Caspian J Intern Med,2014,5(1):9-12.
|
| 35 |
Hajiaghamohammadi AA, Ziaee A, Oveisi S, et al. Effects of metformin, pioglitazone, and silymarin treatment on non-alcoholic fatty liver disease: a randomized controlled pilot study[J]. Hepat Mon,2012,12(8):e6099.
|
| 36 |
Loguercio C, Andreone P, Brisc C, et al. Silybin combined with phosphatidylcholine and vitamin E in patients with nonalcoholic fatty liver disease: a randomized controlled trial[J]. Free Radic Biol Med,2012,52(9):1658-1665.
|
| 37 |
Aller R, Izaola O, Gómez S, et al. Effect of silymarin plus vitamin E in patients with non-alcoholic fatty liver disease. A randomized clinical pilot study[J]. Eur Rev Med Pharmacol Sci,2015,19(16):3118-3124.
|
| 38 |
Federico A, Trappoliere M, Tuccillo C, et al. A new silybin-vitamin E-phospholipid complex improves insulin resistance and liver damage in patients with non-alcoholic fatty liver disease: preliminary observations[J]. Gut,2006,55(6):901-902.
|
| 39 |
孙志新. 水飞蓟宾胶囊联合阿昔莫司胶囊治疗非酒精性脂肪性肝病52例临床观察[J]. 解放军医学杂志,2014,39(10):847-848.
|
| 40 |
戴德茹. 水飞蓟宾联合洛伐他汀对非酒精性脂肪肝的临床疗效[J]. 中国实用医药,2016,11(8):139-140.
|
| 41 |
Trinchet JC, Coste T, Lévy VG, et al. Treatment of alcoholic hepatitis with silymarin. A double-blind comparative study in 116 patients[J]. Gastroenterol Clin Biol,1989,13(2):120-124.
|
| 42 |
Bunout D, Hirsch S, Petermann M, et al. Controlled study of the effect of silymarin on alcoholic liver disease[J]. Rev Med Chil,1992,120(12):1370-1375.
|
| 43 |
Parés A, Planas R, Torres M, et al. Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter trial[J]. J Hepatol,1998,28(4):615-621.
|
| 44 |
Ferenci P, Dragosics B, Dittrich H, et al. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver[J]. J Hepatol,1989,9(1):105-113.
|
| 45 |
Enjalbert F, Rapior S, Nouguier-Soulé J, et al. Treatment of amatoxin poisoning: 20-year retrospective analysis[J]. J Toxicol Clin Toxicol,2002,40(6):715-757.
|
| 46 |
Ganzert M, Felgenhauer N, Schuster T, et al. Amanita poisoning--comparison of silibinin with a combination of silibinin and penicillin[J]. Dtsch Med Wochenschr,2008,133(44):2261-2267.
|
| 47 |
Mengs U, Pohl RT, Mitchell T. Legalon® SIL: the antidote of choice in patients with acute hepatotoxicity from amatoxin poisoning[J]. Curr Pharm Biotechnol,2012,13(10):1964-1970.
|
| 48 |
Grabhorn E, Nielsen D, Hillebrand G, et al. Successful outcome of severe Amanita phalloides poisoning in children[J]. Pediatr Transplant,2013,17(6):550-555.
|
| 49 |
Luangchosiri C, Thakkinstian A, Chitphuk S, et al. A double-blinded randomized controlled trial of silymarin for the prevention of antituberculosis drug-induced liver injury[J]. BMC Complement Altern Med,2015,15:334.
|
| 50 |
Gu J, Tang SJ, Tan SY, et al. An open-label, randomized and multi-center clinical trial to evaluate the efficacy of Silibinin in preventing drug-induced liver injury[J]. Int J Clin Exp Med,2015,8(3):4320-4327.
|
| 51 |
石清红. 水飞蓟宾预防抗结核药所致肝损伤效果的Meta分析[J]. 山东医药,2016,56(8):44-46.
|
| 52 |
Wagoner J, Negash A, Kane OJ, et al. Multiple effects of silymarin on the hepatitis C virus lifecycle[J]. Hepatology,2010,51(6):1912-1921.
|
| 53 |
Biermer M, Schlosser B, Fülöp B, et al. High-dose silibinin rescue treatment for HCV-infected patients showing suboptimal virologic response to standard combination therapy[J]. J Viral Hepat,2012,19(8):547-553.
|
| 54 |
Neumann UP, Biermer M, Eurich D, et al. Successful prevention of hepatitis C virus (HCV) liver graft reinfection by silibinin mono-therapy[J]. J Hepatol,2010,52(6):951-952.
|
| 55 |
Beinhardt S, Rasoul-Rockenschaub S, Scherzer TM, et al. Silibinin monotherapy prevents graft infection after orthotopic liver transplantation in a patient with chronic hepatitis C[J]. J Hepatol,2011,54(3):591-592.
|
| 56 |
Eurich D, Bahra M, Berg T, et al. Treatment of hepatitis C-virus-reinfection after liver transplant with silibinin in nonresponders to pegylated interferon-based therapy[J]. Exp Clin Transplant,2011,9(1):1-6.
|
| 57 |
Mariño Z, Crespo G, D’Amato M, et al. Intravenous silibinin monotherapy shows significant antiviral activity in HCV-infected patients in the peri-transplantation period[J]. J Hepatol,2013,58(3):415-420.
|
| 58 |
Bárcena R, Moreno A, Rodríguez-Gandía MA, et al. Safety and anti-HCV effect of prolonged intravenous silibinin in HCV genotype 1 subjects in the immediate liver transplant period[J]. J Hepatol,2013,58(3):421-426.
|
| 59 |
Rendina M, D’Amato M, Castellaneta A, et al. Antiviral activity and safety profile of silibinin in HCV patients with advanced fibrosis after liver transplantation: a randomized clinical trial[J]. Transpl Int,2014,27(7):696-704.
|
| 60 |
Osinusi A, Meissner EG, Lee YJ, et al. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial[J]. JAMA,2013,310(8):804-811.
|
| 61 |
李传生. 利加隆联合恩替卡韦治疗慢性乙型肝炎疗效观察[J]. 深圳中西医结合杂志,2015,25(22):73-74.
|
| 62 |
蔡建刚，朱婷婷，刘芙蓉, 等. 水飞蓟宾联合恩替卡韦治疗乙型肝炎肝硬化的临床疗效[J]. 世界华人消化杂志,2016,24(12):1898-1902.
|